Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids by Oresic, Matej et al.
  
 University of Groningen
Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids
Oresic, Matej; Hyotylainen, Tuulia; Kotronen, Anna; Gopalacharyulu, Peddinti; Nygren, Heli;





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2013
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Oresic, M., Hyotylainen, T., Kotronen, A., Gopalacharyulu, P., Nygren, H., Arola, J., ... Yki-Jarvinen, H.
(2013). Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids.
Diabetologia, 56(10), 2266-2274. https://doi.org/10.1007/s00125-013-2981-2
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 13-11-2019
ARTICLE
Prediction of non-alcoholic fatty-liver disease and liver fat
content by serum molecular lipids
Matej Orešič & Tuulia Hyötyläinen & Anna Kotronen & Peddinti Gopalacharyulu &
Heli Nygren & Johanna Arola & Sandra Castillo & Ismo Mattila & Antti Hakkarainen &
Ronald J. H. Borra & Miikka-Juhani Honka & An Verrijken & Sven Francque &
Patricia Iozzo & Marja Leivonen & Nabil Jaser & Anne Juuti & Thorkild I. A. Sørensen &
Pirjo Nuutila & Luc Van Gaal & Hannele Yki-Järvinen
Received: 23 May 2013 /Accepted: 10 June 2013 /Published online: 4 July 2013
# The Author(s) 2013. This article is published with open access at Springerlink.com
Abstract
Aims/hypothesis We examined whether analysis of lipids by
ultra-performance liquid chromatography (UPLC) coupled to
MS allows the development of a laboratory test for non-
alcoholic fatty-liver disease (NAFLD), and how a lipid-profile
biomarker compares with the prediction of NAFLD and liver-fat
content based on routinely available clinical and laboratory data.
Methods We analysed the concentrations of molecular lipids
by UPLC-MS in blood samples of 679 well-characterised
individuals in whom liver-fat content was measured using
proton magnetic resonance spectroscopy (1H-MRS) or liver
biopsy. The participants were divided into biomarker-
discovery (n=287) and validation (n=392) groups to build
and validate the diagnostic models, respectively.
Results Individuals withNAFLDhad increased triacylglycerols
with low carbon number and double-bond content while
lysophosphatidylcholines and ether phospholipids were di-
minished in those with NAFLD. A serum-lipid signature
comprising three molecular lipids (‘lipid triplet’) was devel-
oped to estimate the percentage of liver fat. It had a
sensitivity of 69.1% and specificity of 73.8% when applied
for diagnosis of NAFLD in the validation series. The useful-
ness of the lipid triplet was demonstrated in a weight-loss
intervention study.
Conclusions/interpretation The liver-fat-biomarker signa-
ture based on molecular lipids may provide a non-invasive
tool to diagnose NAFLD, in addition to highlighting lipid
molecular pathways involved in the disease.
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1H-MRS Proton magnetic resonance spectroscopy
LC Lipid cluster
LysoPC Lysophosphatidylcholine
NAFLD Non-alcoholic fatty-liver disease
NASH Non-alcoholic steatohepatitis
PC Phosphatidylcholine
ROC Receiver operating characteristic
TG Triacylglycerol
UPLC Ultra-performance liquid chromatography
Introduction
Non-alcoholic fatty-liver disease (NAFLD) is defined as
hepatic fat accumulation exceeding 5–10% of liver weight
that is not due to alcohol, autoimmune, viral or other known
causes [1]. It has been estimated that 30% of adults have a
fatty liver due to non-alcoholic causes [1, 2]. NAFLD pre-
dicts non-alcoholic steatohepatitis (NASH), type 2 diabetes
and cardiovascular disease, independent of obesity [3–5].
NAFLD has also become a prevalent indication for liver
transplantation [6]. As the diagnosis of NAFLD is not as
straightforward as, for example, that of type 2 diabetes, there
is a need to develop diagnostic tools to identify individuals
with NAFLD.
Liver-fat content can be quantified invasively by a liver
biopsy and non-invasively by protonmagnetic resonance spec-
troscopy (1H-MRS), but these methods are unavailable in
clinical practice. Other radiological techniques provide quali-
tative rather than quantitative estimates, and their sensitivity is
limited [7]. Elevated liver-function tests alone are unspecific
and insensitive markers of a fatty liver [8]. Several biomarkers
based on simple biochemical and clinical data have been
developed to predict NAFLD, such as the fatty-liver index
(BMI, waist, triacylglycerols [TGs], γ-glutamyltransferase)
and the commercially available Steatotest (12 variables in an
undisclosed formula) (reviewed in Machado and Cortez-Pinto
[9]). We have recently developed an NAFLD liver-fat score,
which allows identification of individuals with NAFLD with
sensitivity of 86% and specificity of 71% using clinical and
laboratory data (the metabolic syndrome, type 2 diabetes,
fasting insulin and serum alanine aminotransferase [ALT]
and aspartate aminotransferase [AST] concentrations) [10].
However, it is cumbersome and more expensive to assess
compared with a simple laboratory test.
Ideally, diagnostic tests for NAFLD would directly reflect
the changes in lipid composition of the liver and respond to
molecular changes accompanying changes in liver fat such
as those induced by weight loss. We have previously shown
in liver-biopsy studies [11] and by measuring the rates of
lipid production across the splanchnic bed that the more fat
there is in the liver, the greater is the relative abundance of
TGs containing saturated or monounsaturated fatty acids
[12]. These changes could reflect an increase in de novo
lipogenesis, which is increased in NAFLD [13] and produces
only saturated fatty acids, especially palmitic and stearic
acids, which are then converted to respective monounsatu-
rated fatty acids via stearoyl-CoA desaturase-1 (SCD-1)
[14]. As there is considerable similarity between the sources
of fatty acids for intrahepatocellular TGs and for TG secre-
tion by the liver in lipoproteins [13], detailed analysis of
circulating molecular lipids might enable identification of
biomarkers for NAFLD that reflect its pathogenesis. The aim
of the present study was thus to identify novel serum-lipid
markers to estimate liver-fat content and diagnose NAFLD.
We analysed the concentrations of lipids in serum samples of
679 well-characterised individuals in whom liver-fat content
was measured using 1H-MRS or a liver biopsy. The analyses
were performed using an established metabolomics platform
for profiling molecular lipids [15].
Methods
Participants The individuals who participated in the meta-
bolic studies performed at the Universities of Helsinki and
Turku (Finland) were recruited by newspaper advertise-
ments, contact via the occupational health services and from
patients referred to the department of gastroenterology be-
cause of chronically elevated serum transaminase concentra-
tions. The inclusion criteria were: age 18 to 75 years; no
known acute or chronic disease except obesity or type 2
diabetes, based on medical history, physical examination and
standard laboratory tests (blood counts, serum creatinine,
thyroid-stimulating hormone, electrolyte concentrations) and
electrocardiogram; and alcohol consumption less than 20 g
per day. Hepatitis B and C serology, transferrin saturation,
anti-smooth muscle antibodies, anti-nuclear antibodies and
anti-mitochondrial antibodies were measured in all patients
referred to the gastroenterologist because of chronically ele-
vated liver-function tests. Exclusion criteria included use of
glitazones and pregnancy. Elevated liver enzymes (serum
ALT or AST) were not exclusion criteria. The cohort who
participated in the weight-loss intervention study were
recruited at the Antwerp University Hospital (Belgium) from
patients referred to the obesity clinic. The design and enrol-
ment criteria for this study have been previously reported [16].
The study protocol was approved by the ethics committees
of the University Hospitals of Helsinki, Turku and Antwerp.
Each participant provided written informed consent.
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Study design The participants were randomly divided into
biomarker-discovery (n=287) and validation (n=392) groups
to build and validate the model, respectively. All study partic-
ipants (n=679) were used as the second validation group. The
validation and biomarker-discovery groups were comparable
with respect to age, sex, BMI, liver-fat content, prevalence of
NAFLD, waist circumference, type 2 diabetes, BP and fasting
serum glucose, TG, HDL-cholesterol and insulin concentra-
tions (Table 1). The prevalence of metabolic syndrome and
liver-enzyme concentrations were slightly higher and those of
LDL-cholesterol and total serum cholesterol slightly lower in
the validation compared with the discovery group (Table 1).
An unthawed blood sample was available from all par-
ticipants. Of the blood samples used, 78% were citrate
plasma, 16% were heparin plasma and 7% were serum
samples. Studies comparing citrate and heparin plasma
and serum samples from the same participants showed
comparable lipidomics data using each sample type (data not
shown).
Liver-fat content In 369 participants (54%), liver-fat content
was measured using 1H-MRS as previously described [10].
This measurement has been validated against histologically
determined lipid content [17] and against estimates of fatty
infiltration by computed tomography [18] andMRI [19]. The
reproducibility of repeated measurements of liver fat in non-
diabetic participants as determined on two separate occa-
sions in our laboratory is 11% [20].
In 46% of the participants, liver fat was measured using a
liver biopsy. The fat content of the liver biopsy specimens
(percentage of hepatocytes with macrovesicular steatosis)
was determined for all participants, based on haematoxylin-
eosin staining, by an experienced liver pathologist (Johanna
Arola) in a blinded fashion. The percentage of macrovesicular
steatosis was converted to the liver-fat percentage measured
by 1H-MRS and liver histology as previously described [17].
NAFLDwas defined as liver fat ≥55.6 mg TG/g liver tissue or
≥5.56% liver tissue weight [21]. Descriptions of other clinical
and biochemical measurements are provided in the electronic
supplementary material (ESM) Methods section.
Lipidomic analysis with ultra-performance liquid chroma-
tography coupled to MS An established platform based on
ultra-performance liquid chromatography (UPLC; Acquity
Ultra Performance LC; Waters, Milford, MA, USA) coupled
to time-of-flight MS was applied to analyse the aliquots
(10 μl) of serum or plasma sample [15]. The data were
processed by using MZmine 2 open source software [22]
(http://mzmine.sourceforge.net/) and the lipid identification
was based on an internal spectral library or de novo identi-
fication using tandem MS [15]. A detailed description of the
lipidomic-analysis method is provided in ESM Methods.





plasma; fS, fasting serum; GGT,
γ-glutamyltransferase, S-, serum
Characteristic Biomarker-discovery group Validation group p value
n (% men) 287 (33) 392 (39) 0.11a
Age (years) 47±11 47±12 0.58
BMI (kg/m2) 34.7 (30.6, 40.2) 34.8 (30.2, 41.0) 0.37
Waist (cm) 111±17 113±18 0.48
Type 2 diabetes (%) 21 22 0.50a
Metabolic syndrome (%) 61 69 0.034a
Liver fat (%) 4.9 (1.7, 12.4) 4.8 (1.0, 12.1) 0.48
NAFLD (%) 45 45 0.94a
fP-glucose (mmol/l) 5.9±2.0 6.0±1.8 0.28
fS-TGs (mmol/l) 1.40 (1.00, 2.00) 1.40 (1.00, 1.99) 0.98
fS-HDL-cholesterol (mmol/l) 1.25 (1.06, 1.57) 1.21 (1.04, 1.51) 0.33
fS-LDL-cholesterol (mmol/l) 3.01±0.93 2.83±0.90 0.012
Total serum cholesterol (mmol/l) 5.1±1.1 4.9±1.0 0.012
Systolic BP (mmHg) 133±17 134±17 0.28
Diastolic BP (mmHg) 83±11 85±11 0.062
fS-insulin (mU/l) 12 (7, 17) 12 (7, 17) 0.55
S-ALT (U/l) 32 (23, 48) 36 (25, 54) 0.010
S-AST (U/l) 28 (22, 37) 30 (24, 41) 0.005
S-GGT (U/l) 27 (19, 42) 32 (21, 57) 0.006
Use of statins (%) 14 17 0.29a
Use of BP medications (%) 29 36 0.047a
Use of glucose-lowering medication (%) 9 17 0.003a
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Multivariate statistical analysis of lipidomics data The data
were rescaled to zero mean and unit variance to obtain
metabolite profiles comparable with each other for clustering.
Bayesian-model-based clustering was applied on the scaled
data to group lipids with similar profiles across all samples.
The analyses were performed using theMCLUST [23]method,
implemented in R software (www.r-project.org/).
Diagnostic model In order to perform variable selection we
developed a new algorithm based on the method of artificial
life [24, 25]. In brief, the algorithm performs a heuristic
search for combinations of variables that could predict a
specific output variable (either dichotomous or real valued),
by evaluating a population of thousands of evolving models,
in which better models evolve by combining with each other
to produce the next generations of models. The simulation is
continued until the variables selected in the model population
do not change further. We used logistic regression [26] for
dichotomous output (i.e. classification) and ridge regression
[27] for real valued output (i.e. regression) as the modelling
method. The AUCs of the receiver operating characteristic
(ROC) curves were compared using generalised U statistics
[28], implemented with the R package pROC [29].
Results
Diagnosis of NAFLD Using the UPLC-MS-based analytical
platform, a total of 413 molecular lipids were measured in
the biomarker-discovery group. The global lipidome was
first surveyed by clustering the data into a subset of clusters
using Bayesian-model-based clustering [23]. The lipidomic
platform data were decomposed into nine lipid clusters (LCs).
Descriptions of each cluster and the representative lipids are
shown in Table 2. As expected, to a large degree, the clusters
followed different lipid functional or structural groups.
As shown in Fig. 1, several of the clusters had different
average metabolite profiles in participants with NAFLD
(NAFLD+ group) compared with those with normal liver
fat (NAFLD− group). Specifically, there was an overall and
highly significant trend in NAFLD towards increased concen-
trations of TGs containing saturated and monounsaturated
fatty acids (LC9), as well as a lower concentration of
lysophosphatidylcholine (lysoPC) from LC2 and ether lipids
(LC4). In a plot of representative lipids from significantly altered
clusters against liver-fat content (Fig. 2), each of the lipids in the
lipid triplet was significantly correlated with liver-fat content.
Next, we aimed to establish if specific molecular lipids can
be used for the diagnosis of NAFLD. Based on lipidomics in
the biomarker-discovery series, a predictivemodel comprising
a lipid triplet (TG[16:0/18:0/18:1], phosphatidylcholine
[PC][18:1/22:6], PC[O-24:1/20:4]) was derived using an evo-
lutionary algorithm. The results were compared with the
reference model (NAFLD score) derived from selected clini-
cal variables [10] (ESM Fig. 1). The mass spectra confirming
the identity of the minor lipid (PC[O-24:1/20:4]) is shown in
ESM Fig. 2. In the biomarker-discovery series, the lipid-
derived model was comparable with the reference model (no
significant difference between the ROC curves).
The model was independently tested in the validation
series. The lipid triplet showed good generalisation in the
prediction of NAFLD in the validation series (ESM Fig. 1),
with no significant difference in AUC compared with the
reference model. We defined the optimal cut-off point for
classification using the Youden’s index on the biomarker-
discovery series ROC curve. For the diagnostic model based
on the lipid triplet, the optimal cut-off (0.463) resulted in a
diagnostic test with a sensitivity of 69.5% and specificity of
78.6%, 72.4% positive predictive value (PPV), and 76.2%
negative predictive value (NPV). When applied to the vali-
dation series, the sensitivity and specificity were 65.2% and
72.9%. The reference model in combination with its optimal
cut-off point attained a test with a sensitivity of 72.4% and
specificity of 74.1% in the discovery series. The sensitivity
and specificity of the reference model when applied to the
validation series was 75.9% and 59.6%, respectively. Addition-
ally, for the lipidmodel, we defined cut-off points for ‘ruling in’
and ‘ruling out’NAFLD for potential use in pre-screening [30].
The ‘ruling in’ cut-off point 0.661 corresponded to a test with
39.1% sensitivity and 95% specificity in the discovery series,
and showed 44.9% sensitivity and 84.6% specificity when
applied to the validation series. The ‘ruling out’ cut-off point
0.215 corresponded to a test with 95.3% sensitivity and 31.4%
specificity in the discovery series, and showed 85.4% sensitiv-
ity and 54.2% specificity when applied to the validation series
(ESM Fig. 1 and ESM Table 1).
As the lipid triplet included in the NAFLD model includ-
ed an abundant TG together with two polyunsaturated fatty
acid (PUFA)-containing lipids that were both negatively
associated with liver fat (Table 2) and are both common con-
stituents of HDL [31–33], we also tested if TG(16:0/18:0/18:1)
together with HDL-cholesterol would predict NAFLD. The
model was developed from the biomarker-discovery series
using the same method as described above. It performed rea-
sonably well, with an AUC 0.74 (95% CI 0.69, 0.80) in the
discovery series and AUC 0.71 (95% CI 0.67, 0.77) in the
validation series (ESM Fig. 3).
Biomarker discovery of liver fat from serum lipidomic
profile The significant associations of specific lipid and
polar metabolite concentrations with liver-fat content
(Fig. 2) suggested that circulating molecular lipids may be
predictive of liver fat. Using the lipidomics data from the
discovery series, we derived a model to determine the liver-fat
content by applying the artificial-life algorithm and ridge re-
gression as for the NAFLD model. Based on the data in the
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biomarker-discovery series, the following model for liver-fat
content was derived using the concentration of the three model-
selected molecular lipids (PC[O-24:1/20:4], PC[18:1/22:6] and
TG[48:0]):
log10 liver fat %½ ð Þ ¼ 0:0314–0:575
 log10 PC O 24 : 1=20 : 4½ ð Þ–0:537
 log10 PC 18 : 1=22 : 6½ ð Þ þ 0:810
 log10 TG 48 : 0½ ð Þ
Figure 3 shows the performance of the model when ap-
plied to the combined biomarker-discovery and validation
data (ESM Table 2 shows the performance of prediction on
different amounts of liver fat). Performance in the discovery
and validation series, when analysed separately, is shown in
ESM Fig. 4. We also applied the liver-fat model above for the
diagnosis of NAFLD. Figure 3 shows the ROC curves of the
diagnostic performance of the model. Interestingly, this model
not only shows better performance than the original NAFLD
diagnostic model (ESM Fig. 1), but also performs as well as
the reference model. However, it is not significantly better
than the reference model. The optimal cut-off point, as deter-
mined by the Youden’s index, resulted in a test with 69.5%
sensitivity and 75.5% specificity in the biomarker-discovery
series. When applied to the validation series, the sensitivity
was 69.1% and specificity 73.8%. When applied to the com-
bined biomarker-discovery and validation series, the sensitiv-
ity was 69.3% and specificity 74.5%. The sensitivity of the
reference model was 74.6% and specificity 64.8% in the
combined discovery and validation series. The sensitivities
and specificities corresponding to the ‘ruling in’ and ‘ruling
out’ cut-off points are marked in Fig. 3 and ESM Fig. 4.
The correlation coefficient of the lipid triplet and liver-fat
content was higher than that between liver-fat content and
fasting insulin, ASTor fasting total plasma TG concentrations
(ESM Figs 5–7). To evaluate whether adding other biochem-
ical or clinical data improved the prediction of liver fat, we
also trained a model by adding fasting insulin as an additional
term to the lipid triplet, using the artificial-life ridge regression
algorithm as above, but this did not improve the prediction
of liver fat above that observed using the lipid triplet alone
(ESM Fig. 8).
Application of the lipid triplet to characterise the effect of
therapeutic intervention To examine whether the lipid triplet
identified as a marker of liver fat responded to weight loss, we
measured it in serum samples in a recently described 48 week






























LC1 LC2 LC3 LC4 LC5 LC6 LC7 LC8
LC9
Fig. 1 Mean lipid levels within each cluster, shown separately for
patients with NAFLD (NAFLD+, black bars) and without NAFLD
(NAFLD−, white bars) in the biomarker-discovery cohort. The data
for each lipid are scaled to zero mean and unit variance. Statistical
comparison was performed using the two-sided t test. The cluster
summaries are shown in Table 2. Error marks show standard error of
the mean. *p<0.05 vs NAFLD−; ***p<0.001 vs NAFLD−. For LC7
the two groups are different at the marginal significance level (p=0.097)
Table 2 Metabolome and lipidome cluster descriptions
Cluster name Cluster size Cluster description p value Examples of metabolites
LC1 22 Diverse, odd- and short-chain
TGs, ether lipids
0.50 PE(36:6e), TG(46:2) (↑), TG(42:0), TG(49:0) (↑)
LC2 130 Diverse, lysoPCs, SMs, PCs 0.033 lysoPC(16:0) (↓), lysoPC(18:0) (↓), SM(d18:0/18:0),
SM(d18:1/24:1), SM(d18:1/16:0) (↓), PC(34:2), PC(18:1/22:6) (↓)
LC3 30 Ether lipids (PEs) 0.70 PE(34:6e), PE(34:4e), PE(34:3e)
LC4 82 Ether PCs, PEs 0.036 PC(O-24:1/20:4) (↓), PC(34:1e) (↓), PC(34:2p) (↓), PE(38:2) (↓),
PE(36:2) (↓)
LC5 24 PUFA-containing PCs,
PEs and TGs
0.070 PC(38:6), PC(40:6), PE(38:5), TG(58:8) (↑), TG(16:0/16:1/22:6) (↑)
LC6 32 Unknown 0.99
LC7 57 C18:2-containing TGs 0.097 TG(16:0/18:2/18:1), TG(18:1/16:1/18:2), TG(18:1/18:2/18:1)
LC8 4 Unknown 0.11
LC9 32 SFA- and MUFA-containing TGs 7.34×10−6 TG(16:0/18:1/18:1) (↑), TG(16:0/16:0/18:1) (↑),
TG(16:0/18:1/20:1) (↑)
(↑) and (↓) mark significant up- and downregulation, respectively, for individually listed metabolites
p values were determined using the two-sided t test (NAFLD+ vs NAFLD− groups in the biomarker-discovery cohort)
MUFA, monounsaturated fatty acid; PE, phosphatidylethanolamine; SFA, saturated fatty acid; SM, sphingomyelin
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with either placebo or the cannabinoid receptor type 1 blocker
rimonabant [34]. Liver fat was measured using 1H-MRS.
We analysed serum samples obtained before and after
treatment from 12 individuals receiving rimonabant and
from eight individuals receiving placebo (ESM Table 3).
None of the post-intervention samples was included in the
development of the liver-fat marker (discovery or valida-
tion series). In agreement with the reported findings [34],
liver fat determined using the lipid triplet decreased sig-
nificantly in the rimonabant group (ESM Table 3). The
estimated liver fat correlated closely with the lipid triplet
concentration in both intervention arms before, as well as after,
the intervention (Fig. 4).
Discussion
Using molecular lipid-profiling platforms based on combin-
ing chromatography and MS we identified a lipid triplet that
was shown to predict NAFLD. Its diagnostic performance in
the biomarker-discovery and validation cohorts was similar
to the recently reported NAFLD score [10]. The usefulness
of the lipid droplet was demonstrated in a pharmacological
intervention study.
Higher liver-fat content was associatedwith increased serum
concentrations of TG containing saturated or monounsaturated
fatty acids, and decreased concentrations of PUFA-containing
phospholipids and ether lipids. These data are consistent with
those in a much smaller group of individuals, which showed
that TGs with low carbon number and double-bond content are
major constituents of liver fat in human liver biopsies [11] and
that these lipids are also enriched in VLDL particles of insulin-
resistant individuals [31]. Studies using stable isotope tracers
have shown that overproduction of VLDL, rather than a de-
crease in clearance, accounts for hypertriacylglycerolaemia in
NAFLD [35, 36]. The changes in absolute and relative con-
centrations of TG could reflect increased de novo lipogenesis,
which produces saturated fatty acids [14] and is increased in





























Fig. 3 Prediction of liver-fat content from the model including three
lipids, TG(48:0), PC(O-24:1/20:4) and PC(18:1/22:6). (a) The relation-
ship between measured and predicted liver fat (log10 scale on both
axes). Pearson correlation coefficient r 0.54 (p<0.001). Black circles,
men; white circles, women. (b) ROC curve for NAFLD diagnosis
(biomarker-discovery and validation series combined), based on pre-
dicted liver fat, and the ROC curves of the reference model [10]. Test
lipid combination AUC 0.79 (95% CI 0.75, 0.82), reference AUC 0.78
(95% CI 0.74, 0.82). Optimal cut-off point corresponding to the max-
imum sum of sensitivity and specificity: test lipid combination 0.648
(95% CI 0.745, 0.693); reference 0.409 (95% CI 0.648, 0.746). Cut-off
point for 95% sensitivity: test lipid combination 0.353 (95% CI 0.354,
0.938); reference 0.241 (95% CI 0.286, 0.954). Cut-off point for 95%
specificity: test lipid combination 0.918 (95% CI 0.936, 0.343); refer-
ence 0.723 (95% CI 0.924, 0.431). Black curve, biomarker-discovery
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Fig. 2 The relationship between liver-fat content and the selected
representative lipids from the clusters that are significantly altered in
NAFLD: (a) TG(16:0/16:0/18:1) from cluster LC9 (Spearman rank cor-
relation r, 0.45, p<0.001); (b) lysoPC from LC2 (r, −0.32, p<0.001); and
(c) PC(O-24:1/20:4) from LC4 (r −0.31, p<0.001). The regression lines
are drawn as guides
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NAFLD [13]. Consistent with these data, overfeeding carbo-
hydrates increases both liver fat and de novo lipogenesis [37].
In addition, direct measurement of molecular lipids across the
splanchnic bed showed that the fatty liver overproduces satu-
rated and monounsaturated TGs with low double-bond content
in NAFLD [12]. The proportional increase of these TGs in the
serum of individuals with NAFLD is likely, therefore, to di-
rectly reflect their increased amount and production in the liver.
This may explain the recent finding from a prospective study
that more saturated TGs and those with shorter acyl chains
associate with a higher risk of developing type 2 diabetes [38],
as NAFLD both precedes and predicts type 2 diabetes [4].
LysoPCs and PUFA-containing phospholipids including
ether lipids were negatively associated with liver fat and
were, in combination with saturated TGs, included in the
lipid signature predictive of NAFLD and liver-fat content.
These lipids are abundant in HDL particles [31–33] and their
decrease in NAFLD could, therefore, reflect the known
negative association between HDL-cholesterol and liver-fat
content [39, 40]. However, when combined with specific
TGs in the diagnostic model, the specific molecular lipids
were better predictors than HDL-cholesterol.
The lipid triplet, when applied to the combined
biomarker-discovery and validation series, had sensitivity
of 69.3% and specificity 74.5%, while the sensitivity of the
reference model [10] was 74.6% and specificity 64.8%. The
latter figures were lower than the values of 95% for the
NAFLD liver-fat score in the original cohort [10] and those
described for the Steatotest (90% and 70%) [41] and the
fatty-liver index (87% and 86%, respectively) [42]. The
lower sensitivities and specificities of the NAFLD liver-fat
score than reported for the original cohort could reflect the
following: (1) all predictors work best in the cohort in which
they are discovered; and (2) the present cohort included not
only Finnish but also Belgian individuals; and (3) the sample
size in this study is, to date, the largest used to search for a
score predicting steatosis [9].
Although the major usefulness of the present study may
be its insight into the pathogenesis of NAFLD, it may in the
future be useful in clinical practice for both hepatologists and
diabetologists. Such an application would require the devel-
opment of an assay specifically measuring the lipid triplet.
Development of this assay is feasible given that many
methods now use targeted UPLC-MS/MS-based methods
in routine clinical chemistry laboratories. Once such an assay
is set up, the prediction of liver fat using a serum sample
would take less time than the assessment of the components
included in the reference method (metabolic syndrome, type
2 diabetes, fasting insulin and serum ALT and AST concen-
trations) or other methods such as the fatty-liver index [9].
Knowledge of the amount of fat in the liver may help to
select patients who should undergo further examinations,
such as measurement of liver fat by ultrasound methods
(e.g. as recently described by Xia et al [43]), or a liver biopsy,
as NAFLD predisposes to NASH [44]. In patients with type
2 diabetes, the amount of exogenous insulin required to
control hepatic glucose production is directly proportional
to liver fat, independent of obesity and other factors [18, 45].
Such patients might particularly benefit from interventions
effectively reducing liver fat [46]. A laboratory test measur-
ing the currently described lipid triplet may also help in the
follow-up of such individuals.
In conclusion, the lipid triplet identified in the present
study as a marker of NAFLD and liver-fat content sup-
ports data addressing the pathogenesis of NAFLD. The
finding that saturated TG(16:0/18:0/18:1) is the best cir-
culating predictor among TGs suggests that the liver re-
leases TGs that are particularly abundant in it. The other
two lipid species that are deficient in serum are the ones
most abundant in HDL particles, which, in turn, are de-
creased in NAFLD.
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Fig. 4 Comparison of measured and estimated liver fat using the serum
molecular signature in participants before and after intervention with
rimonabant or placebo (log10 scale on both axes). Pearson correlation
coefficient r, 0.53 (p<0.001). White circles, placebo at baseline; white
squares, rimonabant at baseline; black circles, placebo at 48 weeks;
black squares, rimonabant at 48 weeks
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